Evaluation of oral health status in patients receiving antiepileptic medications

Background: Epilepsy is a common neurological disorder of incidence rate 1-2%. Genetic, congenital, developmental, tumors, head trauma and central nervous system infections maybe the cause of epilepsy. This study aimed to determine the prevalence of stomatitis, xerostomia and taste disorder among pa...

Full description

Bibliographic Details
Main Authors: Farqad N Abed, Raja H Al –Jubouri
Format: Article
Language:English
Published: College of Dentistry/ University of Baghdad 2014-06-01
Series:Journal of Baghdad College of Dentistry
Online Access:https://jbcd.uobaghdad.edu.iq/index.php/jbcd/article/view/452
id doaj-2e930311fe434ef6861a7efc88402cfe
record_format Article
spelling doaj-2e930311fe434ef6861a7efc88402cfe2021-09-02T21:18:38ZengCollege of Dentistry/ University of BaghdadJournal of Baghdad College of Dentistry2311-52702014-06-01262Evaluation of oral health status in patients receiving antiepileptic medications Farqad N AbedRaja H Al –JubouriBackground: Epilepsy is a common neurological disorder of incidence rate 1-2%. Genetic, congenital, developmental, tumors, head trauma and central nervous system infections maybe the cause of epilepsy. This study aimed to determine the prevalence of stomatitis, xerostomia and taste disorder among patients taking carbamazepine or sodium valproate and to make salivary analysis for IgA, cystatin c and salivary flow rate. Material and method:This study performed in al- Yarmuk teaching hospital in Baghdad, Samples consist of (70) epileptics half of them treated with carbamazepine and other half treated with sodium valproate, and (18) healthy control group of both genders and with different ages to detect the prevalence of oral manifestations, salivary IgA and cystatin C changes. Results: Salivary IgA is significantly higher in epileptics than healthy group. DMFT is significantly lower in epileptics than in healthy control. GI is hardly affected by epilepsy. Salivary flow rate was significantly lower in epileptics than the healthy control group. On the other hand, cystatin C was obviously higher in epileptics but failed to reach the level of statistical significance. Mucositis in epileptics was significantly higher. Candidal infection and Dysguisia failed to reach the level of statistical difference. Conclusion: The most affected oral measurement by epilepsy was salivary IgA then salivary flow rate followed by DMFT. Cystatin C had a marginal contribution to the context of case –control discrimination.Sodium valproate is safer than carbamazepine when compared by its effects on the oral health. Mucositis, candida infection and dysguisia were lower in epileptics who were treated with Sodium valproate. Salivary flow rate was higher in Sodium valproate - treated group than in carbamazepine group. GI and DMFT were lower in sodium valproate treated group than the carbamazepine group. https://jbcd.uobaghdad.edu.iq/index.php/jbcd/article/view/452
collection DOAJ
language English
format Article
sources DOAJ
author Farqad N Abed
Raja H Al –Jubouri
spellingShingle Farqad N Abed
Raja H Al –Jubouri
Evaluation of oral health status in patients receiving antiepileptic medications
Journal of Baghdad College of Dentistry
author_facet Farqad N Abed
Raja H Al –Jubouri
author_sort Farqad N Abed
title Evaluation of oral health status in patients receiving antiepileptic medications
title_short Evaluation of oral health status in patients receiving antiepileptic medications
title_full Evaluation of oral health status in patients receiving antiepileptic medications
title_fullStr Evaluation of oral health status in patients receiving antiepileptic medications
title_full_unstemmed Evaluation of oral health status in patients receiving antiepileptic medications
title_sort evaluation of oral health status in patients receiving antiepileptic medications
publisher College of Dentistry/ University of Baghdad
series Journal of Baghdad College of Dentistry
issn 2311-5270
publishDate 2014-06-01
description Background: Epilepsy is a common neurological disorder of incidence rate 1-2%. Genetic, congenital, developmental, tumors, head trauma and central nervous system infections maybe the cause of epilepsy. This study aimed to determine the prevalence of stomatitis, xerostomia and taste disorder among patients taking carbamazepine or sodium valproate and to make salivary analysis for IgA, cystatin c and salivary flow rate. Material and method:This study performed in al- Yarmuk teaching hospital in Baghdad, Samples consist of (70) epileptics half of them treated with carbamazepine and other half treated with sodium valproate, and (18) healthy control group of both genders and with different ages to detect the prevalence of oral manifestations, salivary IgA and cystatin C changes. Results: Salivary IgA is significantly higher in epileptics than healthy group. DMFT is significantly lower in epileptics than in healthy control. GI is hardly affected by epilepsy. Salivary flow rate was significantly lower in epileptics than the healthy control group. On the other hand, cystatin C was obviously higher in epileptics but failed to reach the level of statistical significance. Mucositis in epileptics was significantly higher. Candidal infection and Dysguisia failed to reach the level of statistical difference. Conclusion: The most affected oral measurement by epilepsy was salivary IgA then salivary flow rate followed by DMFT. Cystatin C had a marginal contribution to the context of case –control discrimination.Sodium valproate is safer than carbamazepine when compared by its effects on the oral health. Mucositis, candida infection and dysguisia were lower in epileptics who were treated with Sodium valproate. Salivary flow rate was higher in Sodium valproate - treated group than in carbamazepine group. GI and DMFT were lower in sodium valproate treated group than the carbamazepine group.
url https://jbcd.uobaghdad.edu.iq/index.php/jbcd/article/view/452
work_keys_str_mv AT farqadnabed evaluationoforalhealthstatusinpatientsreceivingantiepilepticmedications
AT rajahaljubouri evaluationoforalhealthstatusinpatientsreceivingantiepilepticmedications
_version_ 1721169515186749440